Gene Therapy

Gene Therapy for Mesothelioma

Gene Therapy for Mesothelioma
Therapy Type	Gene Therapy (Experimental)
Primary Approaches	Suicide gene, Immunostimulatory, Oncolytic virotherapy, Tumor suppressor replacement
Most Advanced Trial	TR002 Phase 3 (IFN-α2b)
Key Vector	Adenovirus (replication-incompetent)
Delivery Route	Intrapleural instillation
Pioneering Institution	University of Pennsylvania
Key Investigators	Daniel Sterman, Steven Albelda
Research History	30+ years (since mid-1990s)
FDA-Approved	No (investigational only)
Fast-Track Designation	ONCOS-102 (2021)
Best Survival Data	ONCOS-102: 20.5 months (vs 13.5 chemo alone)
Active Trials	4+ recruiting (2026)

Key Facts — Gene Therapy for Mesothelioma

Gene therapy introduces specific genetic material into cells using viral or non-viral vectors to kill tumor cells, restore lost tumor suppressor function, or stimulate anti-tumor immune responses Mesothelioma was one of the earliest solid tumors targeted by gene therapy in the 1990s because the pleural cavity provides a contained space for regional vector delivery The HSV-tk/ganciclovir suicide gene system was the first approach tested, with two patients surviving more than 6.5 years in long-term follow-up at the University of Pennsylvania Interferon-based gene therapy using adenoviral IFN-α2b (TR002) has advanced to Phase 3 clinical trials — the furthest any mesothelioma gene therapy has progressed The Phase 2 IFN-α2b trial achieved a 25% overall response rate and 88% disease control rate, with median overall survival of 21 months for epithelioid histology patients ONCOS-102, an oncolytic adenovirus expressing GM-CSF, received FDA fast-track designation in 2021 after showing median overall survival of 20.5 months versus 13.5 months with chemotherapy alone Genprex's Reqorsa delivers the TUSC2 tumor suppressor gene via lipid nanoparticles, with preclinical data showing 10 to 33 times greater uptake in tumor cells versus normal cells BAP1 is the most commonly mutated gene in mesothelioma (~60% of cases), and its loss creates vulnerabilities exploitable by EZH2 inhibitors such as tazemetostat CRISPR screening in 2025 identified BUB1 kinase as a high-confidence therapeutic vulnerability specific to mesothelioma cells No gene therapy has received FDA approval for mesothelioma, but multiple approaches are in active clinical trials as of 2026 Anti-vector immunity — the body's immune response against viral delivery vehicles — remains the most significant practical limitation, reducing the efficacy of repeated dosing

What Is Gene Therapy for Mesothelioma?

Gene therapy is defined as the modification of the genetic makeup of cells for therapeutic purposes. Unlike conventional chemotherapy, which uses cytotoxic drugs to kill rapidly dividing cells indiscriminately, gene therapy introduces specific genetic material into cells to kill tumor cells, restore lost tumor suppressor function, or stimulate anti-tumor immune responses. It differs from standard immunotherapy such as checkpoint inhibitors in that it uses viral or non-viral vectors to deliver therapeutic genes directly to the tumor site rather than relying on systemic modulation of the immune system.

Malignant pleural mesothelioma (MPM) accounts for approximately 80% of all mesothelioma cases and presents with dyspnea, pleural effusion, and chest pain in the context of prior asbestos exposure. Several characteristics make MPM uniquely suited for gene therapy. The pleural cavity provides a contained body cavity accessible for regional delivery of gene therapy vectors through intrapleural injection. The thin layer of mesothelial and malignant cells offers a large surface area for efficient and diffuse gene transfer. MPM typically grows along pleural surfaces and infrequently metastasizes to distant organs, making local treatment particularly beneficial. With a median survival of only 6 to 18 months despite standard treatments, the disease course is minimally affected by current therapies, driving the need for novel experimental approaches.

Four major gene therapy strategies have been investigated for mesothelioma over the past three decades. Suicide gene therapy uses an enzyme/prodrug system to kill transduced cells along with nearby bystander cells. Immunostimulatory gene therapy delivers cytokine genes such as interferons to stimulate anti-tumor immunity. Tumor suppressor gene replacement restores lost genetic function in genes such as TUSC2 and BAP1. Oncolytic virotherapy uses engineered viruses that selectively replicate in and kill cancer cells while sparing healthy tissue. A fifth approach — gene-modified cell therapies such as CAR-T cells targeting mesothelin — represents a closely related but distinct modality.

Adenovirus has been the most widely used vector in mesothelioma gene therapy. Replication-incompetent adenoviral vectors can transfect various cell types with high efficiency even when non-dividing, accomplishing high-level but transient gene expression. Their safety record in humans has been excellent, though they trigger significant local and systemic inflammation including neutralizing antibodies. Other vectors tested include vaccinia virus, herpes simplex virus type 1 (HSV-1716), measles virus (Edmonston strain MV-NIS), Newcastle disease virus, reovirus, and emerging non-viral lipid nanoparticles for TUSC2/Reqorsa delivery.

Why Was Mesothelioma One of the First Gene Therapy Targets?

Mesothelioma was among the earliest solid tumors targeted by gene therapy, with research beginning at the University of Pennsylvania in the mid-1990s under the leadership of Daniel Sterman, Steven Albelda, and Larry Kaiser. The choice of mesothelioma as an early gene therapy candidate was driven by several biological and anatomical factors that made the disease particularly amenable to this experimental approach.

The pleural cavity functions as a naturally contained anatomical compartment that allows regional delivery of therapeutic vectors directly to tumor surfaces. When a gene therapy vector is instilled intrapleurally through a catheter or during video-assisted thoracoscopic surgery (VATS), the vector comes into direct contact with the tumor lining rather than being diluted through systemic circulation. This anatomical advantage means that high local concentrations of vector can be achieved at the tumor site while minimizing systemic toxicity — a critical consideration for early-phase clinical safety testing.

The diffuse growth pattern of mesothelioma along pleural surfaces also created a favorable geometry for gene transfer. Unlike solid tumors that form dense masses difficult for vectors to penetrate, the relatively thin sheets of mesothelioma cells coating the pleural surfaces present a large surface area accessible to vector contact. This architectural feature was particularly important for the adenoviral vectors used in early trials, which were most effective at transducing cells on the outer surface of tissue.

The poor prognosis of mesothelioma further justified its selection for experimental gene therapy. In the 1990s, median survival with standard treatment was approximately 12 months, and no effective second-line therapy existed. This dismal outlook provided both clinical rationale and ethical justification for testing novel and unproven therapeutic approaches in affected patients.

Mesothelioma is also characterized by defined genetic alterations — frequent loss of tumor suppressor genes including BAP1 (mutated in approximately 60% of cases), CDKN2A/p16 (deleted in over 80% of cases), and NF2/Merlin (inactivated in 30 to 50% of cases). These well-characterized molecular vulnerabilities provided specific targets for gene replacement strategies and informed the development of precision gene therapy approaches.

How Does Suicide Gene Therapy Work?

The HSV-tk/ganciclovir system is the most extensively studied gene therapy approach in mesothelioma and represents the founding technology of the field's clinical development. A replication-incompetent adenoviral vector delivers the herpes simplex virus thymidine kinase (HSV-tk) gene into tumor cells via intrapleural injection. The HSV-tk enzyme converts the antiviral prodrug ganciclovir, administered systemically, into ganciclovir triphosphate — a toxic metabolite that incorporates into replicating DNA and kills the transduced cell. Critically, the bystander effect means neighboring non-transduced cells are also killed through gap junctions and release of toxic metabolites, which is essential because not every tumor cell takes up the vector.

The Pioneering Penn Clinical Trials

The first-in-human Phase I dose-escalation trial was conducted by Sterman and colleagues at the University of Pennsylvania and published in 1998. Twenty-one previously untreated mesothelioma patients received a single intrapleural dose of replication-incompetent Ad.HSVtk at doses ranging from 1 × 10⁹ to 1 × 10¹² plaque-forming units (pfu), followed by two weeks of systemic ganciclovir at 5 mg/kg twice daily.

This landmark trial established several important findings. Dose-limiting toxicity was not reached even at the highest administered dose. Side effects were minimal and included fever, anemia, transient liver enzyme elevations, bullous skin eruptions, and temporary systemic inflammatory response at the highest dose level. HSV-tk gene transfer was documented in 11 of 20 evaluable patients in a dose-related fashion using RNA PCR, in situ hybridization, immunohistochemistry, and immunoblotting. Strong intrapleural and intratumoral immune responses were generated across multiple dose levels.

A subsequent study of 5 patients added systemic corticosteroids (solumedrol) in an attempt to reduce the inflammatory response and potentially improve gene transfer efficiency. However, the corticosteroids decreased inflammation without improving gene transfer, suggesting that the immune response was an integral component of the therapeutic effect rather than merely a side effect.

Long-Term Survival Results

A critical long-term follow-up study published in 2005 focused on 21 patients who received high-dose therapy where transgene-encoded thymidine kinase protein was reliably identified on immunohistochemical staining. Thirteen patients received an E1/E3-deleted vector, and eight received an E1/E4-deleted vector.

Both vectors were well tolerated and safe. Posttreatment antibody responses against the tumors were consistently observed. Most remarkably, two patients survived more than 6.5 years — both treated with the E1/E4-deleted vector. Given the limited gene transfer observed, the investigators postulated that Ad.HSVtk may have been effective due to induction of antitumor immune responses rather than direct cytotoxicity alone. This critical insight fundamentally shifted subsequent research toward immunostimulatory gene therapy approaches using interferon genes.

Limitations of Suicide Gene Therapy

Several obstacles prevented the HSV-tk/ganciclovir approach from advancing to Phase 3 trials. Gene transfer was limited to the outermost tumor layers, with only a fraction of tumor cells successfully transduced by intrapleural vector delivery. The host immune system rapidly generated neutralizing antibodies against the adenoviral vector, clearing it before maximal gene transfer could occur. Many patients had pre-existing anti-adenoviral antibodies from prior natural exposure to adenovirus, further limiting initial vector efficacy. Dense solid tumor tissue prevented vector distribution beyond superficial layers.

What Has Interferon Gene Therapy Achieved?

Based on the observation that the Ad.HSVtk vector induced powerful anti-tumor immune responses, the Penn group shifted focus toward using adenoviral vectors to deliver interferon genes directly into the pleural space. Type I interferons (IFN-α and IFN-β) augment tumor neoantigen presentation by dendritic cells, induce Th1 polarization, and enhance cytotoxic CD8+ T cell, NK cell, and M1 macrophage function.

Early IFN-β Trials

The initial Phase I dose-escalation study evaluated single-dose intrapleural IFN-β gene transfer using Ad.IFN-β in 10 patients (7 with MPM and 3 with metastatic pleural effusions) at doses ranging from 9 × 10¹¹ to 3 × 10¹² viral particles. Antitumor immune responses were elicited in 7 of 10 patients, including cytotoxic T cells, activation of circulating NK cells, and humoral responses to known tumor antigens such as SV40 large T antigen and mesothelin. Four of 10 patients showed meaningful clinical responses defined as disease stability and regression on PET and CT scans at day 60. Median survival was 449 days — approximately 15 months.

A follow-up Phase I trial evaluated two intrapleural doses of Ad.IFN-β and confirmed that repeated dosing was safe. However, neutralizing anti-adenoviral antibodies rapidly developed after the first dose, significantly limiting the efficacy of the second dose. This finding highlighted the central challenge of viral gene therapy — the body's immune system recognizes the viral vector as a foreign invader and mounts a defensive response that also eliminates the therapeutic vehicle.

The Transition to IFN-α2b

When Ad.IFN-β was no longer commercially available, the program transitioned to adenovirus expressing IFN-α2b. A Phase I study of 9 patients receiving two intrapleural doses spaced 3 days apart showed that gene transfer was augmented by the second dose — a key improvement over the IFN-β experience. Five of 9 patients achieved stable disease or tumor regression at 60 days. The shorter dosing interval allowed the second vector dose to be delivered before full anti-vector antibody development.

Phase 2 Results — The Pivotal Trial

The Phase II pilot and feasibility trial enrolled 40 patients with unresectable MPM who received two intrapleural doses of Ad.IFN-α2b concomitant with a 14-day course of celecoxib, followed by either first-line (n=18) or second-line (n=22) chemotherapy.

Outcome	Result
Overall response rate	25%
Disease control rate	88%
Median OS (epithelioid histology)	21 months
Median OS (non-epithelioid)	7 months
Median OS (first-line cohort)	12.5 months
Median OS (second-line cohort)	21.5 months
2-year survival (second-line)	32%

Overall survival was significantly higher than historical controls in the second-line group, and the combination proved safe across all 40 patients.

TR002 Phase 3 — The Most Advanced Gene Therapy Trial

These Phase 2 results formed the basis for the TR002 Phase 3 trial — a multicenter randomized study of intrapleural adenovirus-delivered interferon alfa-2b (rAd-IFN) combined with celecoxib and gemcitabine versus celecoxib and gemcitabine alone in patients with MPM. This represents the most advanced gene therapy clinical trial in mesothelioma history and the only mesothelioma gene therapy program to reach Phase 3 testing. If successful, TR002 would become the first gene therapy product approved for any form of mesothelioma.

How Does Oncolytic Virotherapy Target Mesothelioma?

Oncolytic viruses are engineered or naturally occurring viruses that selectively replicate in and kill cancer cells while sparing healthy tissue. They function through three complementary mechanisms: direct tumor cell lysis through viral replication, tumor selectivity that exploits abnormal cancer cell signaling pathways, and stimulation of anti-tumor immune responses by releasing tumor neoantigens and inflammatory cytokines. Mesothelioma is an ideal candidate for oncolytic virotherapy given its pleural location accessible for intratumoral injection and its frequently localized growth pattern.

ONCOS-102 — The Leading Oncolytic Virus

ONCOS-102 is the most clinically advanced oncolytic virus for mesothelioma. It is a chimeric adenovirus (Ad5/3) with a partial E1A deletion for tumor selectivity and insertion of a GM-CSF transgene to stimulate immune responses. The GM-CSF component recruits dendritic cells and macrophages to the tumor site, converting immunologically "cold" tumors into "hot" tumors amenable to immune attack.

The pivotal Phase 1/2 randomized study enrolled 31 patients with unresectable MPM. Twenty patients received ONCOS-102 at 3 × 10¹¹ virus particles intratumorally on days 1, 4, 8, 36, 78, and 120 plus standard pemetrexed/cisplatin or carboplatin starting day 22. Eleven patients received chemotherapy alone as controls.

Endpoint	ONCOS-102 + Chemo	Chemo Alone
Median overall survival	20.5 months	13.5 months
Grade ≥3 anemia	15.0%	27.3%
Grade ≥3 neutropenia	40.0%	45.5%
Discontinuation due to adverse events	0 patients	—

ONCOS-102 was well tolerated and led to substantial tumor immune activation including infiltration of CD4+, CD8+, and Granzyme B+ T cells, and increased expression of cytotoxicity genes not observed with chemotherapy alone. Elevated T-cell infiltration at day 36 correlated with survival to month 18. The FDA granted ONCOS-102 fast-track designation in early 2021 based on these promising results.

A Phase Ib/II trial combining ONCOS-102 with a checkpoint inhibitor is underway, based on the rationale that oncolytic virus-mediated tumor inflammation can prime tumors for response to anti-PD-1/PD-L1 blockade.

Other Oncolytic Viruses Tested

Virus	Key Modifications	Clinical Results
HSV-1716	ICP34.5 deletion (neuroattenuated)	Phase I/IIa in inoperable MPM (NCT01721018); effective lysis across MPM subtypes in preclinical models
JX-594 (Pexa-Vec)	Vaccinia; TK deletion + GM-CSF	Phase I: 1 MPM patient achieved partial response lasting >10 weeks
VV-IL-2	Vaccinia; TK deletion + IL-2	Pilot study (6 patients): well tolerated, gene expression up to 3 weeks, no tumor responses
MV-NIS	Measles Edmonston strain + NIS reporter	Phase I enrolling MPM patients (NCT01503177); allows SPECT imaging of viral spread
PV701 (NDV)	Naturally attenuated Newcastle disease virus	Phase I: 1 peritoneal mesothelioma patient had 35% tumor reduction after 30 doses
Reovirus (pelareorep)	Wild-type type 3 Dearing strain	Phase I + docetaxel: 1 MPM patient with minor response

What Role Does Tumor Suppressor Gene Replacement Play?

Mesothelioma is characterized by frequent inactivation of tumor suppressor genes rather than activation of oncogenes, making gene replacement strategies biologically rational. This distinct molecular profile — where the cancer is driven by what is missing rather than what is added — creates clear therapeutic targets for gene delivery approaches.

Key Genetic Alterations in Mesothelioma

Gene	Alteration Frequency	Function
CDKN2A/p16	>80% homozygous deletion	Encodes p16INK4A (Rb pathway regulator) and p14ARF (p53 pathway)
BAP1	~60% somatic mutations/deletions	Deubiquitinating enzyme; epigenetic regulation and DNA damage response
NF2/Merlin	30–50% inactivation	Cytoskeletal scaffolding; Hippo pathway tumor suppressor
TUSC2	Reduced/absent in 84% of cases	Tumor suppressor gene at 3p21.3

BAP1 — The Dominant Mesothelioma Gene

BAP1 is the most commonly altered gene in mesothelioma. In 2011, germline mutations in BAP1 were reported in two families with a high incidence of mesothelioma and uveal melanoma, establishing the BAP1 tumor predisposition syndrome. As a nuclear-localized deubiquitinating enzyme, BAP1 complexes with ASXL1/2 to form the Polycomb repressive deubiquitinase complex (PR-DUB), functioning in epigenetic regulation through chromatin modifications.

While no direct BAP1 gene replacement therapy has entered clinical trials for mesothelioma, BAP1 status has become clinically actionable through a different mechanism. EZH2 inhibitors such as tazemetostat exploit a synthetic vulnerability in BAP1-deficient tumors — when BAP1 function is lost, the tumor becomes dependent on the EZH2 enzyme for survival, creating a druggable target. A Phase II trial showed that patients with BAP1-mutant mesothelioma more than doubled the normal median disease control rate with tazemetostat. The 2025 ASCO mesothelioma guidelines now recommend germline testing for all mesothelioma patients, with BAP1 carriers identified for individualized treatment approaches.

TUSC2/Reqorsa — Nanoparticle Gene Therapy

Genprex's Reqorsa represents a next-generation approach that bypasses the central challenge of anti-viral immunity entirely. Rather than using a viral vector, Reqorsa employs a non-viral lipid nanoparticle to deliver a plasmid expressing the TUSC2 tumor suppressor gene intravenously. TUSC2 expression is reduced or absent in 84% of mesotheliomas, making it a high-frequency target.

Preclinical data presented at the 2024 EORTC-NCI-AACR Symposium showed that TUSC2 gene therapy delivered through Reqorsa significantly slowed tumor growth and triggered cancer cell death in mesothelioma cell lines. The uptake of TUSC2 in tumor cells in vitro was 10 to 33 times the uptake in normal cells, demonstrating remarkable tumor selectivity. This preferential uptake is attributed to the negatively charged lipid nanoparticle formulation being attracted to the negatively charged cancer cell surface.

Genprex has formed a Mesothelioma Clinical Advisory Board and filed provisional patent applications for mesothelioma-specific use, with plans to initiate the first mesothelioma clinical trial. Reqorsa is already being evaluated in lung cancer clinical trials (Acclaim-1 and Acclaim-3), providing safety data that may accelerate the mesothelioma program.

What Have Clinical Trials Demonstrated?

Gene therapy clinical trials in mesothelioma span three decades, from the first-in-human HSV-tk study published in 1998 to actively recruiting Phase 3 trials in 2026. The table below summarizes the key completed and ongoing trials that have shaped the field.

Key Completed Trials

Year	Trial	Agent	Phase	N	Key Results
1998	Sterman et al.	Ad.HSVtk + GCV	I	21	Safe; gene transfer in 11/20; no DLT
2005	Sterman et al.	Ad.HSVtk (long-term follow-up)	—	21	2 patients survived >6.5 years
2007	Sterman et al.	Ad.IFN-β (single dose)	I	10	4/10 clinical responses; 7/10 immune responses; mOS 15 months
2011	Sterman et al.	Ad.IFN-α2b (two doses)	I	9	5/9 stable/regression at day 60
2016	Sterman et al.	Ad.IFN-α2b + celecoxib + chemo	II	40	ORR 25%; DCR 88%; mOS 21 mo (epithelial)
2023	ONCOS-102 + chemo	ONCOS-102 + P/C vs P/C	I/II	31	mOS 20.5 vs 13.5 months

Active and Recruiting Trials (2026)

Trial	Agent	Phase	Status
TR002	Ad.IFN-α2b + celecoxib + gemcitabine vs celecoxib + gemcitabine	Phase 3	Recruiting (multicenter randomized)
ONCOS-102 + CPI	ONCOS-102 combined with checkpoint inhibitor	Phase Ib/II	Recruiting
IK-930	NF2 deficiency-targeting agent	Phase I (FDA fast-track)	Recruiting
TNG908	MTAP mutation-targeting agent	Phase I	Recruiting

How Are Gene Therapy Vectors Delivered?

The method of delivery is a critical determinant of gene therapy efficacy in mesothelioma. Three primary delivery strategies have been employed, each with distinct advantages and limitations that influence which approach is used for different gene therapy modalities.

Intrapleural Instillation

The primary delivery method for mesothelioma gene therapy has been intrapleural instillation through an indwelling pleural catheter, chest tube, or during VATS. This approach ensures high local vector concentration at the tumor surface while minimizing systemic exposure. The Penn trials typically used a single intrapleural infusion through a catheter placed during thoracoscopy. The vector is instilled into the pleural space where it comes into direct contact with the mesothelioma cells lining the pleural surfaces. Patients remain in various positions during and after instillation to distribute the vector across all pleural surfaces.

This approach leverages the same anatomical advantage that makes mesothelioma a gene therapy candidate in the first place — the contained pleural space acts as a natural reservoir that keeps the therapeutic agent concentrated at the disease site. However, intrapleural delivery cannot reach tumor cells that have invaded deeply into the chest wall or diaphragm, which limits its effectiveness in advanced-stage disease with significant tissue invasion.

Intratumoral Injection

For oncolytic viruses like ONCOS-102, direct intratumoral injection is preferred. Using CT or ultrasound guidance, clinicians inject the viral vector directly into measurable tumor masses. This ensures that the replicating virus begins its cycle within the tumor itself, where it can amplify by infecting neighboring cancer cells. The intratumoral approach also induces localized immune responses by releasing tumor neoantigens from lysed cancer cells, potentially triggering systemic anti-tumor immunity against distant metastases — a phenomenon known as the abscopal effect.

Nanoparticle-Based Systemic Delivery

The newest delivery paradigm uses lipid nanoparticles for intravenous (systemic) administration, as exemplified by Genprex's Reqorsa/TUSC2 program. This approach offers several advantages over viral vectors. It avoids the anti-vector immunity problem entirely, since lipid nanoparticles do not trigger the same neutralizing antibody response as viral particles. It allows repeated dosing without diminishing efficacy. And it can potentially reach metastatic disease sites beyond the pleural cavity. The TUSC2-containing nanoparticles show preferential uptake in tumor cells due to their negatively charged surface properties.

Challenges of Repeated Dosing

Anti-vector immunity severely limits the ability to administer multiple doses of the same adenoviral vector. The body's humoral immune response generates neutralizing antibodies after the first exposure, which can inactivate subsequent vector doses before they reach their target. Potential solutions under investigation include vector switching (using different viral serotypes for sequential doses), transient immunosuppression to delay antibody formation, alternative non-viral vectors such as lipid nanoparticles, and optimizing the timing between doses — as demonstrated by the 3-day interval used successfully in the Ad.IFN-α2b trials.

What Are the Safety Risks of Gene Therapy?

Vector-Related Toxicity

Across all adenoviral gene therapy trials in mesothelioma, the safety profile has been remarkably favorable. Side effects of intrapleural adenoviral delivery have consistently included transient fever, flu-like symptoms, anemia, liver enzyme elevations, and inflammatory responses — all generally self-limiting. No dose-limiting toxicity was reached in the initial HSV-tk studies even at the highest administered doses. The ONCOS-102 trials reported no treatment discontinuations due to adverse events, and the overall safety profile of oncolytic virotherapy in mesothelioma has been reassuring.

Anti-Vector Immunity

The development of neutralizing anti-adenoviral antibodies has been the most significant practical limitation of viral gene therapy for mesothelioma. Humoral immune responses were consistently detected after intrapleural vector administration, limiting the efficacy of repeated dosing. In the Ad.IFN-β two-dose trial, the second dose was largely blocked by antibodies generated after the first dose. The Ad.IFN-α2b studies partially addressed this by spacing the two doses only 3 days apart, which augmented gene transfer before full antibody development.

The Jesse Gelsinger Case and Its Impact

No deaths directly attributable to gene therapy have been reported in any mesothelioma gene therapy clinical trial. However, the broader gene therapy field was profoundly affected by the death of Jesse Gelsinger on September 17, 1999, at the University of Pennsylvania during an adenoviral gene therapy trial for ornithine transcarbamylase (OTC) deficiency. Gelsinger, an 18-year-old basically healthy volunteer, received a high dose of adenoviral vector (3.8 × 10¹³ viral particles) intravenously and died of multi-organ failure from a massive immune reaction four days later.

The Gelsinger case occurred at the same institution conducting the mesothelioma gene therapy program under Sterman and Albelda. It led to major regulatory overhaul, increased FDA oversight, criminal investigation, and a general slowdown in gene therapy clinical development across all indications. For mesothelioma gene therapy specifically, the event reinforced the importance of careful dose escalation and thorough safety monitoring. Investigators noted that intrapleural delivery (local and contained) was considered inherently safer than the systemic intravenous delivery used in the Gelsinger trial, because the vector remained concentrated in the pleural space rather than flooding the entire vascular system.

How Does Gene Therapy Compare to Other Immunotherapies?

Gene therapy occupies a distinct but increasingly interconnected position within the broader landscape of mesothelioma immunotherapy. Understanding how it relates to other treatment modalities helps contextualize its potential role in future treatment paradigms.

Modality	Current Status	Relationship to Gene Therapy
Checkpoint inhibitors (nivolumab + ipilimumab)	FDA-approved first-line (non-epithelioid)	May synergize with gene therapy-induced immune priming
CAR-T cells (mesothelin-targeted)	Phase I/II (MSKCC, NCI)	Gene-modified cell therapy; distinct but complementary approach
TTFields (Optune Lua)	FDA HDE-approved (maintenance)	Different mechanism (electric fields); potentially combinable
EZH2 inhibitors (tazemetostat)	Phase II (BAP1-deficient patients)	Small molecule exploiting same genetic target as BAP1 gene replacement
Oncolytic virus + checkpoint inhibitor	Phase Ib/II (ONCOS-102)	Gene therapy–immunotherapy convergence; most promising combination

The approval of nivolumab plus ipilimumab as first-line therapy through the CheckMate 743 trial in 2020 represented the first immunotherapy approved specifically for mesothelioma. While this landmark achievement reduced urgency for some gene therapy approaches, it also opened new combination possibilities. The emerging treatment model positions gene therapy — particularly oncolytic virotherapy — as an immune priming tool that converts immunologically cold tumors into hot tumors amenable to checkpoint blockade. The ONCOS-102 trials showed increased PD-L1 expression and T-cell infiltration after treatment, providing a strong biological rationale for combining oncolytic virotherapy with checkpoint inhibitors.

What Future Developments Are Expected?

CRISPR/Cas9 Applications

A landmark 2025 genome-wide CRISPR screen integrating three MPM cell lines with nonmalignant mesothelial cells identified BUB1 kinase as a high-confidence therapeutic vulnerability. BUB1 ablation leads to cytokinesis failure and multinucleation specifically in mesothelioma cells, and high BUB1 expression is associated with shorter patient survival. This study demonstrates the power of CRISPR screening platforms to identify novel mesothelioma-selective gene targets, though no mesothelioma-specific CRISPR therapeutic clinical trials have yet been initiated.

Scientists are also exploring CRISPR gene editing to directly alter cancer-causing genes and prevent tumor growth. In laboratory settings, researchers have used CRISPR to target and disable genes that help mesothelioma cells survive. While still in early-stage research, CRISPR technology offers the theoretical possibility of precisely correcting the genetic defects that drive mesothelioma — such as restoring BAP1 or CDKN2A function — with a level of specificity that viral vectors cannot achieve.

Nanoparticle-Based Gene Delivery

Building on the mRNA vaccine technology proven during the COVID-19 pandemic, lipid nanoparticle delivery systems offer a non-viral alternative that avoids the anti-vector immunity concerns that have plagued adenoviral gene therapy for decades. Genprex's Reqorsa (TUSC2 in lipid nanoparticles) exemplifies this approach, with its specific targeting of negatively charged cancer cells showing 10 to 33 times greater uptake in tumor versus normal cells. This platform could theoretically be adapted for delivery of other therapeutic genes to mesothelioma, including BAP1, p16, or combination gene cassettes.

Combination Treatment Paradigms

The emerging consensus in the field positions gene therapy as an immune priming tool rather than a standalone curative treatment. The combination of oncolytic viruses or interferon gene therapy with checkpoint inhibitors represents a particularly promising strategy. Viral oncolysis converts immunologically cold tumors to hot tumors amenable to anti-PD-1/PD-L1 therapy by releasing tumor neoantigens, increasing PD-L1 expression, and recruiting immune effector cells to the tumor microenvironment. Multiple trials are now testing these combination strategies, and the results of the ONCOS-102 plus checkpoint inhibitor trial will be closely watched by the mesothelioma treatment community.

Biomarker-Guided Patient Selection

As understanding of mesothelioma molecular subtypes deepens, future gene therapy trials may select patients based on specific tumor genetics rather than treating all comers. BAP1-deficient tumors may be directed toward EZH2 inhibitor sensitivity pathways. CDKN2A/MTAP-deleted tumors may respond to MTAP-targeted therapies such as TNG908. NF2-deficient tumors may benefit from Hippo pathway targeting agents such as IK-930. TUSC2-absent tumors may be prioritized for Reqorsa eligibility. This precision approach could significantly improve response rates by matching the therapy to each tumor's specific molecular vulnerability.

What Do Current Guidelines Say?

NCCN Guidelines (2025)

The 2025 NCCN Guidelines for Pleural Mesothelioma focus on immunotherapy (nivolumab plus ipilimumab) for sarcomatoid and biphasic subtypes as first-line therapy, and chemotherapy (pemetrexed/platinum) for epithelioid subtypes. Gene therapy is not included as a standard treatment recommendation. However, the guidelines emphasize molecular testing and strongly encourage clinical trial participation for patients with progressive disease. The guidelines stress the importance of genetic testing including BAP1 immunohistochemistry and MTAP immunohistochemistry for diagnostic and potentially prognostic purposes — markers directly relevant to gene therapy patient selection.

ASCO Guidelines (2025 Update)

The 2025 ASCO Guideline Update for pleural mesothelioma recommends germline testing for all patients, with specific attention to BAP1 and other cancer predisposition genes. While gene therapy is not included in standard treatment recommendations, Recommendation 7.8 notes that results of somatic testing may have prognostic implications and may be used for clinical trial eligibility or patient-specific targeted therapeutic options. Gene therapy approaches remain in the clinical trial domain, and the guidelines encourage enrollment in available studies for patients who meet eligibility criteria.

Patients diagnosed with mesothelioma should discuss all available clinical trial options with their oncology team, including gene therapy trials for which they may be eligible based on their tumor's molecular profile. The presence or absence of specific genetic alterations such as BAP1 mutations, CDKN2A deletions, or NF2 inactivation may determine eligibility for precision gene therapy trials currently recruiting participants.

Frequently Asked Questions

Is gene therapy FDA-approved for mesothelioma?

No. As of 2026, no gene therapy has received FDA approval for the treatment of mesothelioma. The most advanced program — TR002, an adenoviral interferon alfa-2b combined with celecoxib and chemotherapy — has entered Phase 3 clinical trials, which is the final stage before potential regulatory approval. ONCOS-102, an oncolytic adenovirus, received FDA fast-track designation in 2021, which may accelerate its review process. Multiple other gene therapy approaches remain in Phase 1 or Phase 2 testing.

How does gene therapy differ from chemotherapy and immunotherapy?

Gene therapy introduces specific genetic material into cells using viral or non-viral delivery vehicles (vectors), while chemotherapy uses cytotoxic drugs to kill rapidly dividing cells and standard immunotherapy modulates the existing immune system through systemic agents. Gene therapy can be designed to kill tumor cells directly (suicide gene therapy), stimulate anti-tumor immunity locally (interferon gene therapy), restore missing tumor suppressor function (gene replacement), or selectively lyse cancer cells through engineered virus replication (oncolytic virotherapy).

What is the most promising gene therapy approach for mesothelioma?

Two approaches currently show the most clinical promise. The interferon IFN-α2b program (TR002) has advanced furthest in clinical development, reaching Phase 3 trials based on Phase 2 results showing a 25% overall response rate and 88% disease control rate. ONCOS-102 showed the most impressive survival improvement in randomized testing — median overall survival of 20.5 months versus 13.5 months with chemotherapy alone — and has received FDA fast-track designation.

Are there risks associated with gene therapy?

Gene therapy in mesothelioma has demonstrated a favorable safety profile across three decades of clinical testing. Common side effects of intrapleural adenoviral delivery include transient fever, flu-like symptoms, anemia, and temporary liver enzyme elevations. No treatment-related deaths have been reported in any mesothelioma gene therapy trial. The most significant practical limitation is anti-vector immunity, where the body's immune system generates antibodies against the viral vector, reducing the effectiveness of subsequent doses. Newer non-viral approaches using lipid nanoparticles aim to circumvent this limitation entirely.

Who pioneered gene therapy research for mesothelioma?

Daniel Sterman and Steven Albelda at the University of Pennsylvania are widely regarded as the pioneers of mesothelioma gene therapy. Their first-in-human Phase I trial using adenoviral HSV-tk suicide gene therapy was published in 1998, making mesothelioma one of the earliest solid tumors to receive gene therapy in clinical testing. The Penn team subsequently developed the interferon gene therapy program that has now advanced to Phase 3 trials under the TR002 designation.

How can patients access gene therapy clinical trials?

Patients with mesothelioma should discuss clinical trial availability with their oncology team. Specific genetic testing of the tumor — including BAP1, CDKN2A/MTAP, and NF2 status — may determine eligibility for certain precision gene therapy trials. ClinicalTrials.gov maintains a current registry of all recruiting mesothelioma trials including gene therapy studies. Patients may also contact specialized mesothelioma treatment centers that participate in these trials, including academic medical centers with active gene therapy research programs.

What is CRISPR and how might it help mesothelioma patients?

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is a precise gene-editing technology that allows scientists to cut, modify, or replace specific DNA sequences. In mesothelioma research, a 2025 genome-wide CRISPR screen identified BUB1 kinase as a high-confidence therapeutic vulnerability — meaning that disabling the BUB1 gene specifically kills mesothelioma cells while sparing normal cells. While CRISPR-based therapies for mesothelioma remain in the laboratory research stage, this technology could eventually enable precise correction of the genetic defects driving mesothelioma, such as restoring BAP1 or CDKN2A function.

What is the difference between viral and non-viral gene therapy?

Viral gene therapy uses modified viruses (such as adenovirus, vaccinia virus, or herpes simplex virus) to deliver therapeutic genes into cells. These vectors are efficient at gene transfer but trigger immune responses that can limit repeated dosing. Non-viral gene therapy uses synthetic delivery systems such as lipid nanoparticles to transport genetic material into cells. While historically less efficient at gene transfer, non-viral approaches avoid anti-vector immunity and allow repeated dosing. Genprex's Reqorsa (TUSC2 in lipid nanoparticles) represents the leading non-viral gene therapy approach for mesothelioma.

Related Pages

• Understanding Your Diagnosis
• Pleural Mesothelioma
• CAR-T Cell Therapy for Mesothelioma
• TTFields / Optune Lua for Mesothelioma
• VATS and Thoracoscopic Procedures
• Pleurectomy/Decortication
• Extrapleural Pneumonectomy
• Asbestos Trust Fund Quick Reference
• Veterans Mesothelioma Quick Reference
• Occupational Asbestos Exposure Quick Reference

Free, Confidential Case Evaluation Call (866) 222-9990 or visit dandell.com/contact-us No upfront fees • Experienced representation • National practice

⚠ Statute of Limitations Warning: Filing deadlines vary by state from 1-6 years from diagnosis. Texas allows 2 years from diagnosis or discovery. Contact an attorney immediately to preserve your rights.